跳转至内容
Merck
CN

461350

Sigma-Aldrich

1-Boc-4-哌啶酮

98%

别名:

N-Boc-4-哌啶酮, 丁基4-氧代-1-哌啶羧酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C10H17NO3
CAS号:
分子量:
199.25
Beilstein:
3650236
MDL编号:
UNSPSC代码:
12352100
PubChem化学物质编号:
NACRES:
NA.22

质量水平

方案

98%

mp

73-77 °C (lit.)

官能团

ketone

SMILES字符串

CC(C)(C)OC(=O)N1CCC(=O)CC1

InChI

1S/C10H17NO3/c1-10(2,3)14-9(13)11-6-4-8(12)5-7-11/h4-7H2,1-3H3

InChI key

ROUYFJUVMYHXFJ-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

1-Boc-4-哌啶酮在合成药物中被用作前体,同时也是合成选择性配体的合成砌块。

应用

1-Boc-4-哌啶酮,一个制药结构单元,可用于合成(3E,5E)-3,5-双(2,5-二甲氧基亚苄基)-1-丁氧基羰基哌啶-4-酮(RL197)。它也可以用于合成含有哌啶环结构的螺吡霉素。

警告

避免接触金属。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

In Ho Kim et al.
Bioorganic & medicinal chemistry letters, 17(5), 1181-1184 (2006-12-27)
A novel series of spirorifamycins was synthesized and their antibacterial activity evaluated both in vitro and in vivo. This new series of rifamycins shows excellent activity against Staphylococcus aureus that is equivalent to rifabutin. However, some compounds of the series
The evolving regulatory landscape for fentanyl: China, India, and global drug governance
Wang, Chao and Lassi
International Journal of Environmental Research and Public Health, 19, 2074-2074 (2022)
Atsuya Takami et al.
Bioorganic & medicinal chemistry, 12(9), 2115-2137 (2004-04-15)
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of
John W Clader et al.
Bioorganic & medicinal chemistry, 12(2), 319-326 (2004-01-16)
Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.
Marlon Cowart et al.
Journal of medicinal chemistry, 47(15), 3853-3864 (2004-07-09)
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门